PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Heidelberg Pharma and Huadong announce strategic partnership, including equity investment

Heidelberg Pharma AG and Huadong Medicine Co have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement.

Heidelberg Pharma AG and Huadong Medicine Co have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement.

Heidelberg Pharma has granted an Huadong exclusive license to develop and commercialise HDP-101 and HDP-103 in Asia (excluding Japan), plus exclusive opt-in rights for two more pipeline candidates, with a total deal value of up to USD930 million (EUR825 million).

Huadong will also participate in a rights issue and acquire a percentage of current Heidelberg Pharma shareholdings from existing shareholders including dievini, totalling EUR105 million, making it the second largest investor in the business, behind dievini.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured